Clinical Development Consulting and the Shift to Speed

Key Insights

• Demand is outpacing capacity across healthcare consulting. Most firms said client demand already exceeds what they can deliver – and clients expect far more output for the same fee.
• In life sciences, time became the product. Clients are paying for months saved in development, which moved trial operations into the boardroom.
• Firms are betting on AI in the clinic. Hospitals haven't let it in yet. Nearly every firm expects AI-enabled clinical operations to accelerate, while provider AI still lives mostly in the back office.

---

Healthcare consulting demand is strong. That's the easy part of the story.

The harder part is that what clients buy has changed. Firm leaders described clients who no longer want a better answer at the end of a long engagement. They want the outcome sooner, and they'll pay for the time saved.

We heard this in firm submissions and in conversations with practice leaders for the 2027 Top Healthcare Consulting Firms ranking, and checked it against independent market research. It shows up most clearly in clinical development consulting, where every month removed from a trial timeline has a dollar value a client can calculate.

The ranking covers the full sector – providers, payers, government health, pharma and biotech, medtech, diagnostics, and digital health. Some of what follows held across both care delivery and life sciences. Much of it didn't. Each section says which market it describes.

Clients stopped paying for analysis. They're paying for speed – and firms still selling hours are pricing against the wrong thing.

Watch: 2027 Healthcare Consulting Panel

Demand Is Outpacing Capacity, and Clients Want More for the Same Fee

Most firms told us client demand already exceeds their delivery capacity or is growing faster than they can scale. The rest described steady growth. None described a slowdown.

"The market is up again," one leader said. "Our clients are swamped." The healthcare consulting market isn't short on demand. It's short on the people to deliver it. Transactions and AI-related work were the areas firms most often named as growing fastest.

That should be a pricing advantage. Mostly, it isn't.

Clients know firms are using AI to produce research, analysis, and first drafts faster. One leader summarized what that means at the negotiating table: clients "don't want a discount on what they were doing in the past, but for the same price," they want two to three times the output. That firm grew consulting revenue about 30% this year on a team that barely changed in size.

The budget line hasn't moved. The expectation of what fills it has.

Firms are busier than ever and still facing price pressure, because clients have already priced the firm's productivity gains into the fee.

This held in care delivery and life sciences alike. What differs is what clients will pay a premium for – and in life sciences, the answer is time.

---

---

In Life Sciences, Operational Levers Are Now Strategic Levers

Bringing a drug to market is slow and expensive. According to PhRMA, the average new medicine takes 10 to 15 years and $2.6 billion to develop, counting the failures along the way.

The questions clients bring have moved earlier in the pipeline. One leader said pharma work used to center on getting a product to market and sales force effectiveness. Now it's about pushing assets through development as fast as possible. "Everyone's trying to compress time," the leader said.

Three forces are driving it.

Competition has crowded every therapy area. Early in that leader's career, first in class won and second in class still did fine. "Today, it's really a different paradigm." With curative treatments, the first to market takes a major share, and in rare disease, where one company once owned a therapy area, "everyone has an asset in every therapy area."

AI moved the bottleneck. Discovery is faster because everyone uses AI to identify molecules. More assets reach the clinic, and the constraint shifts to "that middle stage of actually getting it through" human testing.

New sources of assets. Clients are asking how to bring first-in-human assets developed in China to the rest of the world.

The same leader put the result in six words: operational levers are now strategic levers. If you can't get an asset through quickly, "you miss out." The line between strategy and operations is disappearing in life sciences, and firms organized around that line are feeling it.

Regulators have opened room for faster trial design. The FDA's final E6(R3) Good Clinical Practice guidance explicitly embraces flexible, risk-based approaches and new trial technology.

Clinical Development Consulting Is Where the Demand Concentrates

Clinical development consulting covers the decisions between a molecule and an approval: protocol design, indication sequencing, site strategy, enrollment, portfolio prioritization, and regulatory planning.

Three things changed in how clients buy it.

The deliverable is a timeline, not a recommendation. Clients measure the engagement by months saved in start-up and enrollment. One firm reviewed every asset it supported last year and reported a 37% improvement in speed against external benchmarks.

Fees are starting to move at risk. Leaders described clients telling firms they can have the assignment, but they'll be "valued against the actual outcome." One called it early stage in healthcare – but the direction is set, and it favors firms that can actually move the timeline.

AI-enabled clinical operations is the bet. It was the area nearly every firm expected to accelerate over the next two years, on both sides of the market. In life sciences, it's already real: one firm deployed an AI analytics platform for a large drugmaker's site selection, start-up, and enrollment forecasting, and the client rolled it out across all its new studies. The FDA's draft guidance on AI in regulatory decision-making signals the agency expects that work to keep growing.

Adjacent segments are moving too. Tools and diagnostics companies spent several years in a post-pandemic hangover. Many are now cash-flow positive, which brings private equity into a space it couldn't touch before.

Policy and Private Equity Are Compressing Timelines Further

Two more forces are pushing clients toward speed.

The first is pricing policy. Medicare drug price negotiation and the administration's push for most-favored-nation drug pricing changed the math on launch sequencing. One firm expects some manufacturers to delay or reduce launches outside the U.S. Another named pricing and market access among its fastest-growing practices, driven by "so many policy changes" in the last year and a half.

The second is private equity. As one leader put it, "private equity is a sprint with a large team over three weeks." In one diligence, a sponsor's valuation hinged on whether a single diagnostic test could hold off emerging competitors. Technical diligence "reframed the core risk in ways a generalist market model would have missed."

Specialists are getting pulled into that flow earlier. One firm described bankers who once merely "tolerated" consultants at their healthcare conferences now inviting the firm to present as subject-matter experts – and sending sponsors its way.

The client's clock is getting shorter, and the firm that can match it wins the work.

The AI Story Firms Tell Stops at the Hospital Door

Here's where the momentum story gets uncomfortable.

Firms serving health systems expect AI-enabled clinical operations to accelerate just as much as life sciences firms do. But leaders working inside hospitals described something different today: AI mostly in the back office, on data platforms, information management, and administrative automation.

One leader who works with large university hospitals said it plainly. "The Holy Grail, they haven't really touched clinical decision support. That's a bit scary, given that compliance, regulatory issues."

The caution is rational. Data confidentiality is "both a brake" on some projects and a source of new demand for AI assurance and governance advice, one leader said. But the gap has two consequences for firms.

First, the care delivery side of the AI bet depends on hospitals crossing a line they haven't crossed. Firms forecasting growth there are forecasting a change in client behavior, not just client demand.

Second, firms describe AI as the accelerant they bring to clients. Clients have already concluded it's the accelerant firms use on themselves – which is why they expect more output for the same fee. The industry is selling AI-driven speed while its clients are using AI to negotiate its prices down.

What This Means for Firm Leaders

Price the time, not the hours. If your work shortens a trial, a launch, or a deal, put a value on the months saved and anchor the conversation there.

Measure speed against a benchmark. A firm that can say how much faster its clients' assets moved than external analogs has a sales argument no capability list can match.

Put fees at risk where you can measure the outcome. Outcome-based pricing is early in healthcare. Start where your track record is strongest, before clients start asking for it by default.

Show your AI leverage before the client assumes it. Tell clients where your AI productivity goes. If you don't, they'll assume it should come off the invoice.

Be precise about which side of the divide your momentum is on. Growth in clinical development does not transfer to health system work, and buyers know it. Claim momentum in the segment where you have it.

The Bottom Line

Healthcare consulting has more demand than it can staff. That hasn't translated into pricing power, because clients have changed what they're paying for.

In life sciences, they're paying for time. In care delivery, they're paying for margin. In both, they expect the firm's own productivity gains to show up in the fee.

The firms gaining ground in 2027 sell the outcome and the clock it runs on. The firms selling analysis by the hour are competing for a budget that's quietly moving somewhere else.

FAQ: Healthcare Consulting Market Momentum

What is clinical development consulting?

Clinical development consulting helps pharma, biotech, and medtech companies make decisions between discovery and approval: protocol design, indication sequencing, site strategy, enrollment, portfolio prioritization, and regulatory planning. In 2027, clients increasingly measure it by months saved rather than by recommendations delivered.

Is the healthcare consulting market growing?

Yes. Most firms we heard from said client demand exceeds what they can deliver, and none described a slowdown. The wider profession is growing too: the Bureau of Labor Statistics projects management analyst employment to grow 10% from 2025 to 2035, much faster than average.

What do private equity firms hire healthcare consultants for?

Mostly commercial and technical due diligence on provider platforms, medtech and diagnostics assets, and pharma services businesses, plus post-acquisition value creation. The work often runs as a three-week sprint and favors firms that can staff experts quickly.

Why are pharma companies so focused on speed to market?

Development takes years and billions of dollars, and competing assets increasingly target the same indications. First to market often takes the major share, and every month saved extends time on the market.

How are healthcare consulting firms using AI?

In life sciences, AI shows up in trial design, site selection, and enrollment forecasting. In care delivery, it's concentrated in back-office functions and data platforms. Nearly every firm expects AI-enabled clinical operations to grow, but clinical decision support in hospitals remains largely untouched.

Do these trends apply to providers and life sciences equally?

No. Demand outpacing capacity and pressure for more output held across both. The premium on speed and the rise of pricing and market access work are life sciences findings. Management Consulted's ranking covers both markets and maps segment leaders separately.

---

Related reading:

• Every Healthcare Consulting Firm Now Claims the Same Differentiator
• Every Firm Wants the Hybrid Hire. Almost None Are Building One.
• Healthcare Consulting Is Turning Into a Products Business